FloBio

Executive Summary

FloBio is a San Diego-based diagnostics company developing a precision approach to rapid diagnosis of bleeding and clotting risk in emergency, trauma, and critical care settings. Founded in 2016, the company aims to address the critical need for timely hemostasis assessment, where minutes can determine patient outcomes. FloBio's technology was recognized as a semi-finalist in the 2022 AACC Disruptive Technology Competition, highlighting its potential to transform coagulation testing at the point of care. With no disclosed funding rounds or commercial products to date, the company appears to be in the early-stage development or regulatory clearance phase. The growing demand for rapid, decentralized diagnostics in trauma and emergency medicine positions FloBio as a promising player, though execution and regulatory risks remain. If successful, its platform could reduce mortality and improve clinical decision-making in time-sensitive scenarios.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for Point-of-Care Coagulation Device40% success
• Q3 2026Publication of Clinical Validation Study in Peer-Reviewed Journal60% success
• Q1 2027Strategic Partnership or Distribution Agreement with Major Hospital System30% success